Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2017 (← Previous) (Next →)

Filing Date: Apr 7, 2017

Total Value: $137.5B (100.0% shares, 0.0% debt)

Holdings (8)

— Achaogen, Inc. 23.5%

Value $32.32B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Audentes Therapeutics, Inc. 22.4%

Value $30.79B Shares 1,806,832 Est. Cost $17810.00 Unrealized —

— Clovis Oncology, Inc. 18.9%

Value $25.94B Shares 407,416 Est. Cost $56000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 15.0%

Value $20.56B Shares 2,215,384 Est. Cost $20.09 Unrealized -58.6%

— ImmuneDesign Corp. 10.9%

Value $15.02B Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Second Sight Medical Products, Inc. 4.0%

Value $5.436B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— CymaBay Therapeutics, Inc. 3.3%

Value $4.509B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— OpGen, Inc. 2.1%

Value $2.937B Shares 2,554,211 Est. Cost $1150.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Achaogen, Inc.	1,281,152	$32.32B	23.5%	$13050.00	—	Common Stock	004449104
—	Audentes Therapeutics, Inc.	1,806,832	$30.79B	22.4%	$17810.00	—	Common Stock	05070R104
—	Clovis Oncology, Inc.	407,416	$25.94B	18.9%	$56000.00	—	Common Stock	189464100
OCUL	Ocular Therapeutix, Inc.	2,215,384	$20.56B	15.0%	$20.09	-58.6%	Common Stock	67576A100
—	ImmuneDesign Corp.	2,208,210	$15.02B	10.9%	$7580.00	—	Common Stock	45252L103
—	Second Sight Medical Products, Inc.	4,492,975	$5.436B	4.0%	$1210.00	—	Common Stock	81362J100
—	CymaBay Therapeutics, Inc.	1,048,601	$4.509B	3.3%	$9830.00	—	Common Stock	23257D103
—	OpGen, Inc.	2,554,211	$2.937B	2.1%	$1150.00	—	Common Stock	68373L109